Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Current Assets (2021 - 2026)

Indivior Pharmaceuticals has reported Current Assets over the past 6 years, most recently at $667.0 million for Q1 2026.

  • For Q1 2026, Current Assets fell 24.46% year-over-year to $667.0 million; the TTM value through Mar 2026 reached $667.0 million, down 24.46%, while the annual FY2025 figure was $652.0 million, 21.16% down from the prior year.
  • Current Assets for Q1 2026 was $667.0 million at Indivior Pharmaceuticals, up from $652.0 million in the prior quarter.
  • Over five years, Current Assets peaked at $1.3 billion in Q4 2022 and troughed at $652.0 million in Q4 2025.
  • A 5-year average of $927.2 million and a median of $902.5 million in 2025 define the central range for Current Assets.
  • Biggest five-year swings in Current Assets: fell 0.16% in 2023 and later tumbled 34.21% in 2024.
  • Year by year, Current Assets stood at $1.3 billion in 2022, then decreased by 0.16% to $1.3 billion in 2023, then tumbled by 34.21% to $827.0 million in 2024, then dropped by 21.16% to $652.0 million in 2025, then increased by 2.3% to $667.0 million in 2026.
  • Business Quant data shows Current Assets for INDV at $667.0 million in Q1 2026, $652.0 million in Q4 2025, and $922.0 million in Q3 2025.